Phospho-BRCA1抗体|Phospho-BRCA1
Antibody，BRCA1，BRCA pSer 1280，Breast Cancer Gene 1，Breast Cancer 1，Early Onset； Breast-Ovarian Cancer Susceptibility- 询价
- 艾美捷BioVision
- 美国
- 3674-100
- 2025年07月16日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 克隆性：
多克隆
- 抗体英文名：
Phospho-BRCA1 Antibody，BRCA1，BRCA pSer 1280，Breast Cancer Gene 1，Breast Cancer 1，Early Onset； Breast-Ovarian Cancer Susceptibility
- 规格：
100 ug
产品名称：Phospho-BRCA1抗体|Phospho-BRCA1 Antibody，BRCA1，BRCA pSer 1280，Breast Cancer Gene 1，Breast Cancer 1，Early Onset； Breast-Ovarian Cancer Susceptibility
【产品形式】：艾美捷为您提供的Phospho-BRCA1抗体产品为100 ug 无色溶液，其浓度为0.5 mg/ml，溶解于包含有50%甘油， 1% BSA， 0.02%硫柳汞 的PBS （pH 7.2）缓冲液中.请将该Phospho-BRCA1抗体产品置于-20 ℃冷冻保存，建议分装使用以避免反复冻融.
【背景资料】：BRCA1 is a breast cancer susceptibility gene that was localized to chromosome 17q. Mutations within this gene are believed to account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. The BRCA1 gene is expressed in numerous tissues， including breast and ovary， and encodes a predicted protein of 1863 amino acids. Like many other genes involved in familial cancer， BRCA1 appears to encode a tumor suppressor， a protein that acts as a negative regulator of tumor growth.
BioVision的公司总部在美丽的旧金山湾地区，它是全球生命科学公司的领导者.BioVision在开发和研究细胞凋亡检测分析、代谢检测方面具有 卓越的影响力.包括检测各种检测分析试剂盒、相关特色抗体、重组蛋白及细胞因子和酶等多种产品，以及其他创新的研究工具.其产品覆盖细胞凋亡研究、能量代 谢、细胞/组织蛋白提取、氧化应激与损伤、代谢与肥胖症、细胞增殖与毒性、信号转导、干细胞研究等领域.作为多家知名品牌的中国总代理以及中国区域代理， 艾美捷与BioVision一起为研究者们提供最好、最新的细胞生物学研究工具而不断扩大产品及服务质量.
点击：Phospho-BRCA1抗体，查看更详细产品说明，更多应用、储存、价格、货期等信息请致电400-6800-868垂询BioVision中国区域授权总代理艾美捷科技有限公司。
关键词：BRCA，Phospho-BRCA1抗体
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Ovarian Cancer Gene Therapy with BRCA1An Overview
The human breast and ovarian cancer susceptibility gene BRCA1 is a tumorsuppressor gene which is mutated and lost in hereditary breast and ovarian cancer, and has both alleles mutated in approximately 10-15% of cases of sporadic ovarian cancer
Developing Functional Assays for BRCA1 Unclassified Variants
Women with a family history of breast cancer have mutations in one of the breast cancer susceptibility genes, BRCA1 or BRCA2 . Since the discovery of these two genes, around 100,000 women worldwide have undergone genetic testing
Generation and Analysis of Brca1 Conditional Knockout Mice
in breast cancer formation. Cre-loxP-mediated tissue-specific knockout was employed to overcome this obstacle. We found that the presence of a ploxP-neo -loxP cassette in intron 10 of Brca1 resulted in severe interference with gene expression. The neo
技术资料暂无技术资料 索取技术资料
